메뉴 건너뛰기




Volumn 111, Issue 1, 2008, Pages 236-242

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; GAMMA INTERFERON; HLA A ANTIGEN; LEUKEMIA ANTIGEN; MESSENGER RNA; MONTANIDE ISA 51; PROTEINASE 1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; WT1 PROTEIN;

EID: 38049188363     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-08-108241     Document Type: Article
Times cited : (307)

References (31)
  • 1
    • 0029838112 scopus 로고    scopus 로고
    • Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
    • Molldrem J, Dermime S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450-2457.
    • (1996) Blood , vol.88 , pp. 2450-2457
    • Molldrem, J.1    Dermime, S.2    Parker, K.3
  • 2
    • 0030841573 scopus 로고    scopus 로고
    • Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units
    • Molldrem JJ, Clave E, Jiang YZ, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood. 1997;90:2529-2534.
    • (1997) Blood , vol.90 , pp. 2529-2534
    • Molldrem, J.J.1    Clave, E.2    Jiang, Y.Z.3
  • 3
    • 0033826799 scopus 로고    scopus 로고
    • Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
    • Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-1023.
    • (2000) Nat Med , vol.6 , pp. 1018-1023
    • Molldrem, J.J.1    Lee, P.P.2    Wang, C.3
  • 4
    • 0141889279 scopus 로고    scopus 로고
    • Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation
    • Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892-2900.
    • (2003) Blood , vol.102 , pp. 2892-2900
    • Rezvani, K.1    Grube, M.2    Brenchley, J.M.3
  • 5
    • 0037105370 scopus 로고    scopus 로고
    • CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia
    • Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100:2132-2137.
    • (2002) Blood , vol.100 , pp. 2132-2137
    • Scheibenbogen, C.1    Letsch, A.2    Thiel, E.3
  • 6
    • 34248148589 scopus 로고    scopus 로고
    • Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity
    • Rezvani K, Price D, Brenchley J, et al. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy. 2007;9:245-251.
    • (2007) Cytotherapy , vol.9 , pp. 245-251
    • Rezvani, K.1    Price, D.2    Brenchley, J.3
  • 7
    • 38049112538 scopus 로고    scopus 로고
    • Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]. ASH Annual Meeting Abstracts. 2004;104:259.
    • Qazilbash MH, Wieder E, Rios R, et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]. ASH Annual Meeting Abstracts. 2004;104:259.
  • 8
    • 0030737629 scopus 로고    scopus 로고
    • High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
    • Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 1997;90:1217-1225.
    • (1997) Blood , vol.90 , pp. 1217-1225
    • Bergmann, L.1    Miething, C.2    Maurer, U.3
  • 9
    • 0029069227 scopus 로고
    • Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
    • Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995;9:1060-1067.
    • (1995) Leukemia , vol.9 , pp. 1060-1067
    • Menssen, H.D.1    Renkl, H.J.2    Rodeck, U.3
  • 11
    • 0036361833 scopus 로고    scopus 로고
    • Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis
    • Sugiyama H. Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol Med. 2002;68:223-237.
    • (2002) Methods Mol Med , vol.68 , pp. 223-237
    • Sugiyama, H.1
  • 12
    • 0038011942 scopus 로고    scopus 로고
    • Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes
    • Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol. 2003;21:1988-1995.
    • (2003) J Clin Oncol , vol.21 , pp. 1988-1995
    • Cilloni, D.1    Gottardi, E.2    Messa, F.3
  • 13
    • 0028130136 scopus 로고
    • WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
    • Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071-3079.
    • (1994) Blood , vol.84 , pp. 3071-3079
    • Inoue, K.1    Sugiyama, H.2    Ogawa, H.3
  • 14
    • 0031048878 scopus 로고    scopus 로고
    • Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia
    • Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89:1405-1412.
    • (1997) Blood , vol.89 , pp. 1405-1412
    • Inoue, K.1    Ogawa, H.2    Sonoda, Y.3
  • 15
    • 0037370833 scopus 로고    scopus 로고
    • The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia
    • Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101:1698-1704.
    • (2003) Blood , vol.101 , pp. 1698-1704
    • Ogawa, H.1    Tamaki, H.2    Ikegame, K.3
  • 16
    • 0034176750 scopus 로고    scopus 로고
    • Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1
    • Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198-2203.
    • (2000) Blood , vol.95 , pp. 2198-2203
    • Gao, L.1    Bellantuono, I.2    Elsasser, A.3
  • 17
    • 0033966369 scopus 로고    scopus 로고
    • HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide
    • Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-293.
    • (2000) Blood , vol.95 , pp. 286-293
    • Ohminami, H.1    Yasukawa, M.2    Fujita, S.3
  • 18
    • 0034112824 scopus 로고    scopus 로고
    • Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
    • Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics. 2000;51:99-107.
    • (2000) Immunogenetics , vol.51 , pp. 99-107
    • Oka, Y.1    Elisseeva, O.A.2    Tsuboi, A.3
  • 19
    • 20444378186 scopus 로고    scopus 로고
    • Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: Implications for vaccine development and adoptive cellular immunotherapy
    • Gannage M, Abel M, Michallet AS, et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol. 2005;174:8210-8218.
    • (2005) J Immunol , vol.174 , pp. 8210-8218
    • Gannage, M.1    Abel, M.2    Michallet, A.S.3
  • 20
    • 31544461292 scopus 로고    scopus 로고
    • Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer
    • Gillmore R, Xue SA, Holler A, et al. Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res. 2006;12:34-42.
    • (2006) Clin Cancer Res , vol.12 , pp. 34-42
    • Gillmore, R.1    Xue, S.A.2    Holler, A.3
  • 21
    • 29344436442 scopus 로고    scopus 로고
    • T-Cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: Identification, quantification, and characterization
    • Rezvani K, Brenchley JM, Price DA, et al. T-Cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005;11:8799-8807.
    • (2005) Clin Cancer Res , vol.11 , pp. 8799-8807
    • Rezvani, K.1    Brenchley, J.M.2    Price, D.A.3
  • 22
    • 34548857324 scopus 로고    scopus 로고
    • Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes following allogeneic stem-cell transplantation for acute lymphoblastic leukemia (ALL)
    • Rezvani K, Yong ASM, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes following allogeneic stem-cell transplantation for acute lymphoblastic leukemia (ALL). Blood. 2007;110:1924-1932.
    • (2007) Blood , vol.110 , pp. 1924-1932
    • Rezvani, K.1    Yong, A.S.M.2    Savani, B.N.3
  • 23
    • 0742324477 scopus 로고    scopus 로고
    • Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity
    • Mailander V, Scheibenbogen C, Thiel E, et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia. 2004;18:165-166.
    • (2004) Leukemia , vol.18 , pp. 165-166
    • Mailander, V.1    Scheibenbogen, C.2    Thiel, E.3
  • 24
    • 0042347518 scopus 로고    scopus 로고
    • Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis
    • Oka Y, Tsuboi A, Murakami M, et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol. 2003;78:56-61.
    • (2003) Int J Hematol , vol.78 , pp. 56-61
    • Oka, Y.1    Tsuboi, A.2    Murakami, M.3
  • 25
    • 4644289323 scopus 로고    scopus 로고
    • Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
    • Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101:13885-13890.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , pp. 13885-13890
    • Oka, Y.1    Tsuboi, A.2    Taguchi, T.3
  • 26
    • 9144271651 scopus 로고    scopus 로고
    • Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): A Europe against cancer program
    • Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program. Leukemia. 2003;17:2474-2486.
    • (2003) Leukemia , vol.17 , pp. 2474-2486
    • Beillard, E.1    Pallisgaard, N.2    van der Velden, V.H.3
  • 27
    • 30144445384 scopus 로고    scopus 로고
    • Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
    • Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood. 2006;107:205-212.
    • (2006) Blood , vol.107 , pp. 205-212
    • Yong, A.S.1    Szydlo, R.M.2    Goldman, J.M.3    Apperley, J.F.4    Melo, J.V.5
  • 28
    • 9144222001 scopus 로고    scopus 로고
    • Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: A Europe Against Cancer program
    • Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer program. Leukemia. 2003;17:2318-2357.
    • (2003) Leukemia , vol.17 , pp. 2318-2357
    • Gabert, J.1    Beillard, E.2    van der Velden, V.H.3
  • 29
    • 0030691757 scopus 로고    scopus 로고
    • Phenotypic and functional separation of memory and effector human CD8 T cells
    • Hamann D, Baars PA, Rep MH, et al. Phenotypic and functional separation of memory and effector human CD8 T cells. J Exp Med. 1997;186:1407-1418.
    • (1997) J Exp Med , vol.186 , pp. 1407-1418
    • Hamann, D.1    Baars, P.A.2    Rep, M.H.3
  • 30
    • 0034329745 scopus 로고    scopus 로고
    • CD27 is required for generation and long-term maintenance of T cell immunity
    • Hendriks J, Gravestein LA, Tesselaar K, et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol. 2000;1:433-440.
    • (2000) Nat Immunol , vol.1 , pp. 433-440
    • Hendriks, J.1    Gravestein, L.A.2    Tesselaar, K.3
  • 31
    • 2942597447 scopus 로고    scopus 로고
    • WT1 gene expression: An excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients: results from a single-centre study
    • Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients: results from a single-centre study. Br J Haematol. 2004;125:590-600.
    • (2004) Br J Haematol , vol.125 , pp. 590-600
    • Ostergaard, M.1    Olesen, L.H.2    Hasle, H.3    Kjeldsen, E.4    Hokland, P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.